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Novel anti-obesity effects of beer hops
compound xanthohumol: role of AMPK
signaling pathway
Janaiya S. Samuels, Rangaiah Shashidharamurthy and Srujana Rayalam*
Abstract
Background: Obesity alters adipose tissue metabolic and endocrine functioning, leading to an increased adiposity
and release of pro-inflammatory cytokines. Various phytochemicals have been reported to contribute to the beiging
of white adipose tissue in order to ameliorate obesity by increasing thermogenesis. Here, we show that the prenylated
chalcone, xanthohumol (XN), induces beiging of white adipocytes, stimulates lipolysis, and inhibits adipogenesis of
murine 3T3-L1 adipocytes and primary human subcutaneous preadipocytes and these effects are partly mediated by
the activation of the AMP-activated protein kinase (AMPK) signaling pathway.
Methods: 3T3-L1 adipocytes and primary human subcutaneous preadipocytes were differentiated using a standard
protocol and were treated with various concentrations of XN, dorsomorphin, an AMPK inhibitor, or AICAR, an AMPK
activator, to investigate the effects on adipogenesis, beiging and lipolysis.
Results: XN induced beiging of white adipocytes as witnessed by the increased expression of beige markers CIDE-A
and TBX-1. XN increased mitochondrial biogenesis, as evidenced by increased mitochondrial content, enhanced
expression of PGC-1α, and the thermogenic protein UCP1. Following 24 h of treatment, XN also increased oxygen
consumption rate. XN stimulated lipolysis of mature 3T3-L1 and primary human subcutaneous adipocytes and
inhibited adipogenesis of maturing adipocytes. XN activated AMPK and in turn, XN-induced upregulation of UCP1,
p-ACC, HSL, and ATGL was downregulated in the presence of dorsomorphin. Likewise, an XN-induced decrease in
adipogenesis was reversed in the presence of dorsomorphin.
Conclusions: Taken together, XN demonstrates anti-obesity effects by not only inducing beiging but also decreasing
adipogenesis and inducing lipolysis. The anti-obesity effects of XN are partly mediated by AMPK signaling pathway
suggesting that XN may have potential therapeutic implications for obesity.
Keywords: Xanthohumol, 3T3-L1 cells, Beiging, Obesity, AMPK signaling, UCP1, Lipolysis, Thermogenesis, Oxygen
consumption rate, Human primary subcutaneous adipocytes, ACC
Background
Obesity develops when energy intake, in the form of food,
exceeds energy expenditure [1] and is primarily character-
ized by excessive adiposity [2]. There are two functionally
and morphologically distinct types of adipose tissue: white
adipose tissue (WAT) and brown adipose tissue (BAT),
both of which are mediators of energy homeostasis. WAT
functions to store energy in the form of lipids in white
adipocytes and secretes adipokines amongst other factors
including leptin, adiponectin, tumor necrosis factor α
(TNF-α), to regulate energy metabolism and immunometa-
bolism [3, 4]. BAT functions as an energy dissipating,
thermogenic adipose tissue because of its enhanced
mitochondrial content and uncoupling protein 1 (UCP1)
[5]. In response to specific stimuli, such as beta-adrenergic
stimulation or cold exposure, WAT can acquire brown-like
characteristics. This process is referred to as “beiging”.
Differentiation of WAT to beige adipose tissue (BeAT) has
been demonstrated in vivo [6] and in vitro [7] to improve
the metabolic profile and increase thermogenesis.
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Many phytochemicals such as guggulsterone, curcumin,
and resveratrol inhibit adipogenesis, stimulate lipolysis in
adipocytes, and have been recently proposed to act as
beiging agents [7–9]. The mechanisms driving these
responses are not as well defined. Minimal attention has
been directed towards exploring the beiging potential of
phytochemicals or the molecular mechanisms behind it. A
recent study demonstrated that 3T3-L1 adipocytes are a
useful model to study lipid droplet formation and adipo-
genesis [10]. Thermogenesis has been shown to decrease
adiposity and ameliorate diabetes in both mice and adult
humans [11–13].
Following this model, the current study sought to inves-
tigate if the anti-obesity phytochemical, xanthohumol
(XN), a prenylated flavonoid extracted from the hops
plant Humulus lupus, can drive mitochondrial biogenesis
and beiging in 3T3-L1 and human subcutaneous adipo-
cytes. We also sought to determine if XN’s anti-obesity ef-
fects are mediated through the adenosine-monophosphate
protein kinase (AMPK) signaling pathway. Our in vitro
and in vivo data provides novel evidence of XN’s role in
the modulation of improving the metabolic profile.
AMPK is a master metabolic switch and is believed to
be expressed in a number of tissues including BAT. The
thermogenic activities of BAT are activated by AMPK
[14]. BAT activation is stimulated in response to cold con-
ditions resulting in the phosphorylation of AMPK to begin
to increase thermogenesis. AMPK is an enzyme complex
composed of three subunits, the catalytic α subunit and
the two regulatory β and γ subunits. The α1 isoform is the
predominant isoform expressed in adipose tissue [15].
AMPK is phosphorylated at Thr172 of the α subunit and
as a result, becomes biologically active [16].
In our metabolic organs that function to maintain energy
homeostasis, like adipose tissue, phosphorylated-AMPK
(p-AMPK) inhibits anabolic processes and upregulates
catabolic processes. p-AMPK works to enhance fatty acid
oxidation by the phosphorylation of acetyl-CoA carboxylase
(ACC), thereby increasing the incidence of fatty acid deg-
radation [17].
AMPK’s role in adipose tissue metabolism has been well
characterized [18] and studies have demonstrated that
flavonoids like curcumin and resveratrol-induced beiging
of adipocytes is dependent upon AMPK activation [4, 7].
Xanthohumol has also been demonstrated to activate
AMPK [19] but its correlation between beiging and
AMPK activation remains unknown. Therefore, in this
study, we aimed to investigate the potential relationship
between XN-mediated beiging and AMPK signaling.
XN has been shown to possess anti-carcinogenic,
anti-oxidant, and anti-diabetic properties [20–22]. It has
been suggested that the chemical structure of XN is re-
sponsible for its wide range of biological activities. The XN
molecule is comprised of two aromatic rings substituted
with hydroxyl and methoxyl groups, and a prenyl unit.
Because of its prenyl and – OCH3 group, XN is highly lipo-
philic and has a strong affinity for biological membranes
[23]. Hirata et al., reported that XN inhibits the cholesteryl
ester transfer protein (CETP), resulting in an increase in
high density lipoprotein levels. This inhibitory effect can be
attributed to XN’s prenyl group and chalcone structure
[24]. Costa et al., demonstrated that XN consumption in
high-fat diet fed mice prevented weight gain, decreased
blood glucose levels, triglyceride, and cholesterol levels, and
improved insulin sensitivity [25]. XN also activated AMPK
signaling pathway, suppressing lipogenesis [25]. Oral
administration of XN improved inflammatory markers and
the metabolic profile in diet-induced obese C57BL/6 J mice
[26]. However, XN’s beiging effects on adipocytes and the
underlying mechanisms remain to be understood.
Methods
Cell culture of 3T3-L1 adipocytes
Dulbecco’s Modification of Eagle’s Medium (DMEM;
Corning, Manassas, VA, USA) supplemented with 10% calf
serum (CS; Invitrogen, Grand Island, NY, USA) and 1%
penicillin streptomycin (PS; Sigma-Aldrich, St. Louis, MO,
USA) was used to culture the 3T3-L1 mouse embryo prea-
dipocyte cell line (Zenbio, Research Triangle Park, NC,
USA) at 37 °C in a 5% CO2 incubator. Two day post
confluent preadipocytes were maintained in differentiation
induction medium I (DM I) comprised of 1 mg/ml of insu-
lin (Ins; Sigma-Aldrich, St. Louis, MO, USA), 5 μM of dexa-
methasone (Dexa; Sigma-Aldrich, St. Louis, MO, USA),
0.5 mM of isobuytlmethylxanthine (IBMX; Sigma-Aldrich,
St. Louis, MO, USA), and 1 μM of rosiglitazone (Rosi;
Sigma-Aldrich, St. Louis, MO, USA) for 3 days in DMEM
plus 10% fetal bovine serum (FBS; Invitrogen, Grand Island,
NY, USA) and 1% PS. Following DM I, cells were then
maintained in differentiation medium II (DM II) containing
10% FBS, 1% PS, 1 mg/ml of Ins, and 1 μM of Dexa. Unless
otherwise stated, cells were maintained in DM II for 4–
6 days before treatment and analysis and until cells ma-
tured with a minimum of 90% lipid droplet accumulation.
DM II maintenance medium was changed every other day.
XN 6.25 μM and XN 25 μM were the two optimal doses
used in this study based on cell viability assays. To test the
effects of 5-Amionimidazole-4-carboxamide (AICAR; Santa
Cruz Biotechnology, Dallas, TX, USA) and dorsomorphin
(Dorso; Abcam, Cambridge, MA, USA) on AMPK activity,
mature 3T3-L1 adipocytes were treated with AICAR 2 mM
or dorsomorphin 10 μM for one hour.
Cell culture of primary human subcutaneous adipocytes
Primary human subcutaneous preadipocytes were pur-
chased from Lonza (Alpharetta, GA, USA). Preadipocytes
were cultured in preadipocyte growth medium (PGM) sup-
plemented with 10% FBS, 2 mM L-glutamine, 30 μg/mL of
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gentamycin sulfate, and 15 ng/mL of amphotericin B
(Lonza, Alpharetta, GA, USA). Differentiation of human
subcutaneous adipocytes was initiated using complete
PGM supplemented with insulin, dexamethasone, indo-
methacin, rosiglitazone, and IBMX (replenished every other
day; Lonza, Alpharetta, GA, USA). Adipocytes were ma-
tured for 10 days before stimulation with XN.
Cytotoxicity
Confluent mature 3T3-L1 and primary human subcuta-
neous adipocytes were treated with 0.1% DMSO vehicle
control or XN for 24 to 96 h. Cell viability was measured
using the Prestoblue™ Cell Viability Reagent according to
the manufacturer’s protocol. The absorbance of metabol-
ically active cells were quantified 1 h after incubation in
the reagent using the Biotek Synergy HT microplate
reader at 570 nm.
Immunoblot analysis
Cell lysates were prepared using ice cold RIPA Lysis and
Extraction buffer, complete with protease and phosphatase
inhibitors (ThermoFisher Scientific, Grand Island, NY,
USA). Following protein estimation, as determined by the
Pierce BCA Protein Assay Kit (ThermoFisher Scientific,
Grand Island, NY, USA), cell extract was diluted in 4X
sample buffer and heated for 5 min at 95 °C before 4–20%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
After electrophoresis, samples were transferred to a polyvi-
nylidene difluoride (PVDF) membrane using a Trans-blot
Turbo system (Bio-Rad, Hercules, California, USA) and
then blocked for 1 h with Tris buffered saline plus 0.1%
Tween 20 (TBS-T) containing 5% bovine serum albumin
(BSA). Following blocking, the membrane was incubated
for 1 h with 1:1000 dilutions in primary antibodies,
anti-UCP1, anti-CIDE-A, anti-TBX1, anti-phospho-AMPK
(Thr172), anti-phospho-ACC (Ser79), anti-AMPK (α1/2),
(all from Abcam, Cambridge, MA, USA), anti-PGC-1α,
anti-ZIC1, (Novus Biologicals, Littleton, CO, USA), and
anti-β-actin (Santa Cruz Biotechnology, Cambridge, MA,
USA). After three washes with TBS-T buffer, the membrane
was incubated for 45 min at room temperature with sec-
ondary antibodies conjugated to IRDye 800 and developed
using the Odessey CLX imaging system (LiCor Biosciences,
Lincoln, NE, USA). Relative protein levels were quantified
using Image Studio Ver. 5.2 (LiCor Biosciences, Lincoln,
NE, USA).
Mitochondrial content
Mature 3T3-L1 adipocytes were treated with 0.1% DMSO,
XN 6.25 μM, XN 25 μM, and Iso 10 μM for 24 h and in-
cubated with Mitotracker® Green FM (Invitrogen, Grand
Island, NY, USA) as per the manufacturer’s instructions.
Mitochondrial activity was measured using the Biotek
Synergy HT (Winooski, VT, USA) microplate reader at
516 nm.
Oil red O staining
DMSO and XN treated cells were induced to differentiate
for 4–8 days, followed by washing with phosphate
buffered saline (PBS), fixation with 10% formalin for 1 h at
room temperature, and washing again three times with
deionized water. A 6:4 mixture of Oil Red O solution
(0.6% Oil Red O dye in isopropanol) and water was added
to the cells for 20 min followed by a wash four times with
deionized water. Finally, hematoxylin was layered over the
cells and incubated for one minute, then rinsed. Lipid
droplets were imaged under phase contrast using the
EVOS FL Auto Imaging System (ThermoFisher Scientific,
Grand Island, NY, USA) microscope. The Oil Red O stain-
ing is a biological agent used only for the assessment of
lipid content. Therefore, it does not quantitatively meas-
ure total cell number.
AdipoRed™ adipogenesis assay
Both 3T3-L1 and primary human subcutaneous preadipo-
cytes were treated with 0.1% DMSO, XN 6–25 μM, dorso-
morphin 10 μM or AICAR 2 mM during the adipogenesis
period for 8–10 days and the lipid accumulation was quan-
tified using the AdipoRed™ assay (Lonza, Alpharetta, GA,
USA) per the manufacturer’s protocol. AdipoRed is a solu-
tion of the hydrophilic stain Nile Red. Mature adipocytes
treated with 0.1% DMSO, XN 25 μM, dorsomorphin
10 μM, or AICAR 2 mM for 72 h were also assayed on day
10 for lipid quantification. Lipid quantification was obtained
using the Biotek Synergy HT (Winooski, VT, USA) micro-
plate reader at a fluorescence of 485/590 nm. Lipid content
to the number of cells present in each well was normalized
for the AdipoRed™ adipogenesis assay.
Oxygen consumption rate
3T3-L1 premature adipocytes were seeded into a 96-well
plate at a density of 10,000 cells/well. Cells were grown to
confluence and differentiated into mature adipocytes as
per the described protocol above. Mature adipocytes were
treated with XN 6.25 or 25 μM or isoproterenol 10 μM
for 24 h prior to the start of the Oxygen Consumption
Rate Assay Kit, MitoXpress® Xtra HS Method (Cayman
Chemical, Ann Arbor, MI, USA). Antimycin A 1 μM was
used as a negative control to determine oxygen consump-
tion rate (OCR). Time-resolved fluorescence was obtained
over an hour and twenty minutes.
Statistical analysis
All data were expressed as the mean ± SEM. All assays
were performed in triplicate for a minimum of three inde-
pendent experiments. Comparisons were made by using
One-way ANOVA on GraphPad Prism software, followed
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by Tukey’s post hoc tests. Statistical significance was re-
ported as * P < 0.05 or ** P < 0.01. Means denoted with dif-
ferent letters are representations of comparisons between
each treatment groups at a P < 0.05 significance level.
Results
XN does not produce cytotoxic effects in 3T3-L1
adipocytes
Mature 3T3-L1 and primary human subcutaneous adipo-
cytes were treated with 0.1% DMSO, XN 6–50 μM for 24
to 96 h. Following incubation for 24 h, XN 6.25–25 μM
was not significantly cytotoxic to adipocytes in both cell
types (Fig. 1 and Additional file 1). Kirkwood et al., dem-
onstrated that low concentrations of XN acutely increases
uncoupled respiration while higher doses inhibited respir-
ation [27]. Additionally, the plasma levels of XN in HFD
rats fed low (1.86 mg/kg BW) and medium (5.69 mg/kg
BW) doses of XN achieved 50 ± 14 and 107 ± 46 nM
respectively (p > 0.05), while high dose of XN (16.9 mg/kg
BW) achieved significantly higher levels of plasma XN
(389 ± 153 nM) [28]. While it is difficult to translate in
vivo doses to in vitro doses, based on previous in vitro
studies published and our current cell viability data, we
have selected low (6.25 μM) and high (25 μM) concentra-
tions of XN for the subsequent experiments.
XN induces beiging of mature 3T3-L1 and increases
mitochondrial biogenesis
To investigate the beiging effect of XN, 3T3-L1 adipocytes
were stimulated with XN 6.25–25 μM and isoproterenol
10 μM, as a positive control. XN significantly increased the
expression of the beige adipocyte specific marker CIDE-A
in a dose-dependent manner (Fig. 2). ZIC1, a classic brown
adipocyte marker, showed no significant upregulation when
3T3-L1 adipocytes were stimulated with XN 6.25–25 μM
Fig. 1 XN did not induce cytotoxicity in 3T3-L1 and primary human
adipocytes. XN 6.25–25 μM treatment for 24 to 96 h in mature, 3 T3-L1
adipocytes did not induce cytotoxicity. XN stimulation of primary human
subcutaneous adipocytes did not alter cell viability at 6.25–25 μM. All
data are presented as mean ± SEM. Statistical significance between
control and treatment groups is depicted as ** P< 0.01
Fig. 2 XN treatment induces expression of brown/beige fat markers.
XN stimulation of 3T3-L1 and upregulates beige markers CIDE-A and
ZIC1. All data are presented as mean ± SEM. Statistical significance
between control and treatment groups is depicted as * P < 0.05, and
** P < 0.01
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(Fig. 2), suggesting XN-induced beiging. To determine
if XN increases mitochondrial biogenesis, a character-
istic of the beiging of white adipocytes, MitoTracker®
Green was conducted. As shown in Fig. 3a, mitochondrial
content was markedly elevated in XN-treated groups and
this was further confirmed by Western blot analysis of
PGC-1α, a central driver of mitochondrial biogenesis in adi-
pocytes (Fig. 3b). Furthermore, increased expression of the
mitochondrial uncoupling protein 1 (UCP1, Fig. 3c), a
thermogenic marker, an increase in OCR (Fig. 3d), and a
strikingly significant upregulation of the beige adipocyte
marker, TBX-1 (Fig. 3c), strongly support the role of XN in
driving the induction of the beiging of white adipocytes.
XN regulates lipid metabolism in 3T3-L1 adipocytes
To establish XN’s multi-faceted anti-obesity effects on
3T3-L1 and primary human subcutaneous adipocytes, we
examined whether XN inhibits preadipocyte differenti-
ation. Preadipocytes were treated with XN 6.25–25 μM
and 0.1% DMSO vehicle control on day 0 until day 7 of
differentiation. As visualized by Oil Red O staining (Fig. 4),
XN decreased the number and size of lipid droplets in
both 3T3-L1 and primary human subcutaneous adipo-
cytes, suggesting that XN inhibits adipogenesis and sup-
presses lipid accumulation. Lipid content was normalized
to cell number as assessed by cell viability assay.
XN stimulates the phosphorylation of AMPK in mature
3T3-L1 adipocytes
AMPK is an important regulator of metabolic homeostasis
within the cell [29, 30]. A consequence of the activation of
AMPK signaling is lipid metabolism modulation, mito-
chondrial biogenesis, and a decrease in blood glucose levels
[30]. Therefore, we sought to investigate the effect of XN
on AMPK phosphorylation. XN treatment of mature
3T3-L1 adipocytes significantly activated AMPK as evi-
denced by the enhanced expression levels of p-AMPK,





Fig. 3 XN increases mitochondrial content, oxygen consumption
rate, and upregulates thermogenic marker expression in 3T3-L1
adipocytes. a. Various doses of xanthohumol (6.25 and 25 μM) were
incubated with mature, 3T3-L1 adipocytes, followed by quantification
of mitochondrial content using MitoTracker® Green FM assay. All data
are presented as the mean ± SEM. Means denoted with different letters
are statistically different, P < 0.05. b. Protein expression levels of PGC-1α,
a regulator of mitochondrial metabolism in 3T3-L1 adipocytes after
24 h of treatment with XN or isoproterenol. c. UCP1 and TBX1 protein
expression levels post-24 h XN or Iso stimulation. d. OCR as determined
by the Oxygen Consumption Rate Assay Kit following 24 h of treatment
with XN or isoproterenol. All data are presented as mean ± SEM.
Statistical significance between control and treatment groups is
depicted as *P < 0.05, **P < 0.01
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Inhibition of AMPK decreases the thermogenic effects of
XN on 3T3-L1 adipocytes
To identify the possible mechanism underlying the beiging
effect of XN, the selective AMPK inhibitor, dorsomorphin,
was used to determine UCP1 protein expression levels.
When mature 3T3-L1 adipocytes were treated with XN
25 μM, results showed an increase in UCP1 expression.
However, this effect was reversed by co-incubation of dor-
somorphin with XN, suggesting that XN-induced beiging
is mediated via AMPK signaling pathway (Fig. 5). Com-
bined treatment with XN and AICAR resulted in a poten-
tiated effect in UCP1 expression in comparison to XN or
AICAR treatment alone.
XN regulates adipogenesis and lipolysis through the
AMPK pathway
Literature suggests that AMPK is crucial for the mediation
of preadipocyte maturation [31]. To investigate the effects
Fig. 4 XN inhibits preadipocyte differentiation and adipogenesis. Oil Red O staining was performed to assess the maturation of 3T3-L1 adipocytes.
AdipoRed™ assay was used to quantitate XN-induced suppression of lipid accumulation in 3T3-L1 adipocytes and primary human subcutaneous
adipocytes. All data are presented as mean ± SEM. Statistical significance between control and treatment groups is shown as * P < 0.05, ** P < 0.01
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of AMPK on XN-induced inhibition of adipogenesis,
maturing preadipocytes were treated with test compounds
for 0–7 days. AdipoRed™ assay results showed that XN
decreased lipid content by 49% ± 6 when compared to the
control. AICAR treatment alone decreased lipid content
by 8% ± 22 when compared to the control. To the
contrary, XN in the presence of AICAR decreased lipid
content by 51% ± 7. Dorsomorphin increased lipid content
significantly by 61.5% ± 4.29. Noteworthy, XN + dorso-
morphin increased lipid content by 42.25% ± 4.78 (Fig. 6a)
indicating the reversal of XN-induced inhibition on
adipogenesis.
Lipolysis implies the breakdown of triacylglycerols in ad-
ipocytes and subsequent release of glycerol and fatty acids.
Increased expression of adipose triglyceride lipase (ATGL)
and hormone-sensitive lipase (HSL), key enzymes involved
in the intracellular degradation of triacylglycerols, suggests
augmented lipolysis. In our study, XN increased the
expression of HSL and ATGL indicating an increase in
lipolysis. Interestingly, in the presence of dorsomorphin,
XN decreased the expression of both HSL and ATGL indi-
cating the role of AMPK in XN-induced lipolysis (Fig. 6c).
Moreover, AMPK regulates lipid metabolism via the phos-
phorylation and subsequent inactivation of ACC, the rate
limiting enzyme involved in fatty acid biosynthesis. Here,
we report that XN stimulates the phosphorylation of ACC
(Fig. 6c), notably, in the presence of AICAR, we observed
significant potentiated effects, further supporting its role in
fatty acid oxidation mediated through the AMPK pathway.
Discussion
The current study provides novel insights into the
anti-obesity effects of XN and the signaling pathways in-
volved. We have successfully demonstrated that mature
3T3-L1 adipocytes stimulated with XN induces the beige
phenotype and drives thermogenic programming through
Fig. 5 Effect of XN, dorsomorphin, and AICAR on AMPK activation and expression of UCP1. Mature adipocytes were treated for one hour and p-AMPK,
total AMPK, and UCP1 protein expression levels were measured. All data are presented as the mean ± SEM. Means denoted with different letters are
statistically different, P < 0.05
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significant upregulation of beige-fat specific proteins such
as UCP1, PGC-1α, TBX-1, and CIDE-A. TBX-1 is a
beige-fat specific marker and beige adipocytes are highly
enhanced with TBX-1 [6]. Similarly, the thermoregulatory
marker CIDE-A has been shown to be enhanced in BeAT
and is considered a beige marker [32]. In contrast, ZIC1 is
preferentially expressed in brown adipocytes [33]. In-
creased expression of UCP1 increases glycolytic rate due
to reduced efficiency of ATP formation [34]. Here we
report that XN-induced upregulation of UCP1 expres-
sion is accompanied by an increase in the oxygen
consumption rate.
A key characteristic of brown fat and beige fat is the in-
creased numbers of mitochondria [35]. Our data suggests
that XN significantly increases mitochondrial biogenesis in
mature 3T3-L1 adipocytes accompanied by the upregula-
tion of PGC-1α, the central regulator of mitochondrial bio-
genesis and thermogenic programming [36]. Additionally,
UCP1 expression was elevated in 3T3-L1 adipocytes upon
stimulation with XN, confirming mitochondria oxidation
and the acquisition of thermogenic properties [37].
XN was reported to induce apoptosis in mature adipo-
cytes and inhibit adipogenesis in the mouse 3T3-L1 adipo-
cyte cell line [38]. To the contrary, Mendes and colleagues
claimed that XN does not improve the metabolic profile
linked to obesity [39]. Our results are in agreement with
Yang et al. [38], findings and confirm the anti-adipogenic
effects of XN under in vitro conditions.
Previous studies provide evidence that pharmacological
and genetic approaches to activate AMPK may improve
the metabolic profile [40–42]. Therefore, activation of the
AMPK signaling pathway is crucial to achieving and
maintaining energy homeostasis [43]. Our data demon-
strates that XN significantly upregulates the expression of
p-AMPK, and this effect is reversed with the inhibition of
p-AMPK. Flavonoids such as curcumin, chrysin, and quer-
cetin induce the brown-like phenotype in 3T3-L1 adipo-
cytes [7, 44, 45]. In particular, resveratrol-induced beiging
in inguinal WAT was mediated through the activation of
AMPKα1 [4]. Likewise, curcumin-induced browning was
found to be mediated through the activation of the AMPK





Fig. 6 XN-induced inhibition of adipogenesis and stimulation of
lipolysis is reversed in the presence of AMPK inhibitor, dorsomorphin.
a 3T3-L1 preadipocytes were treated on day 0 until day 7 of maturation
and lipid accumulation was quantified by AdipoRed™ assay.
b Differentiated, mature adipocytes were stimulated with XN,
dorsomorphin, or AICAR on day 10 for 72 h and Oil Red O
staining was performed to measure lipid content. c Whole cell
lysates were extracted and Western blotting experiments conducted to
quantitate the expression of HSL (6c), ATGL (6c), and p-ACC (6c) protein
levels post 1 h XN, dorso, or AICAR stimulation. All data are presented
as the mean ± SEM. Means denoted with different letters are
statistically different, P < 0.05
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significantly increased the expression of the thermo-
genic protein UCP1, and this upregulation is medi-
ated partly through the activation of the AMPK
pathway as evidenced by the arrest of UCP1 expres-
sion with XN plus dorsomorphin.
The anti-adipogenic effects of flavonoids have been
suggested to be regulated via the AMPK signaling path-
way in 3T3-L1 adipocytes [46, 47], however, the role of
AMPK in regulating lipolysis has been controversial. Yin
et al., reported that AMPK activation is essential in pro-
moting lipolysis in vitro [48] while in vivo data demon-
strated that AMPK activation is anti-lipolytic [49]. Our
data shows that XN suppressed adipocyte differentiation,
reduced the accumulation of lipid content and lipid
droplet size, increased oxygen consumption rates, and
increased enzymes involved in fatty acid oxidation.
Noteworthy, this anti-adipogenic and lipolysis effect of
XN was abolished in the presence of dorsomorphin.
These results are in agreement with the effects of curcu-
min in the presence of dorsomorphin [7], confirming the
role of AMPK in phytochemical-induced lipolysis in adi-
pocytes. Furthermore, we incubated cells with XN plus
AICAR with the goal of demonstrating additive or syner-
gistic effects. Combined treatment of XN with AICAR
resulted in potentiated HSL, ATGL, p-AMPK/AMPK,
UCP1, and p-ACC expression. However, no potentiated
inhibition of adipogenesis was noticed with XN plus
AICAR and warrants further investigation. Activation of
AMPK by XN represents a novel approach to
anti-obesity therapies, and suggests a role for AICAR in
combination therapies.
Several pathways have been identified as being re-
quired in the beiging of adipocytes, including the
mTOR signaling pathway [50]. Interestingly enough,
the activation of AMPK inhibits mTOR and crosstalk
between these two pathways has been studied. While
AMPK activation is crucial to the brown adipocyte dif-
ferentiation process and functioning in brown and
beige fat [50–53], inhibition of mTOR signaling during
the earlier stages of differentiation attenuates brown
adipogenesis and cell number, suggesting that brown
adipogenesis is dependent upon mTOR activation [50].
In contrast, pharmacological inhibition of AMPK with
the indirect inhibitor iodotubercidin at days 0 or 5
blocked brown adipocyte differentiation while this
inhibition during days 7 to 10 increased lipid accumula-
tion [50]. This data suggests a negative crosstalk between
the mTOR/AMPK pathways essential throughout the
beiging of WAT.
Taken together, these results provide a novel insight into
the molecular mechanism behind XN’s multi-faceted
anti-obesity effects. Notably, the XN-induced activation of
AMPK results in the beiging of mature 3T3-L1 adipo-
cytes, enhanced lipolysis and inhibition of adipogenesis.
Conclusion
In conclusion, findings from this study demonstrate that
XN possesses anti-obesity effects like inhibition of adipo-
genesis, induction of beiging and lipolysis, making for an
attractive pharmacological drug therapy for the treatment
and prevention of obesity. In vitro studies using 3T3-L1
and primary human adipocytes provide novel evidence of
XN’s role in the induction of beiging and the signaling
pathways involved.
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